2017年,在两款嵌合抗原受体T细胞免疫疗法(chimeric antigen receptor T-cell immumotherapy,CAR-T)细胞产品获批后,推进了全球细胞免疫治疗的研究。本文将对近一年来已发表的和第59届美国血液病学会(American Society of Hematology,A...2017年,在两款嵌合抗原受体T细胞免疫疗法(chimeric antigen receptor T-cell immumotherapy,CAR-T)细胞产品获批后,推进了全球细胞免疫治疗的研究。本文将对近一年来已发表的和第59届美国血液病学会(American Society of Hematology,ASH)会议中关于CAR-T细胞治疗血液恶性肿瘤的研究进展做一综述。展开更多
2016年是血液恶性肿瘤免疫治疗取得众多进展的一年,其中细胞免疫治疗和抗体免疫治疗尤为突出。本文将对近一年来已发表的以及第58届美国血液病学会(American Society of Hematology,ASH)会议中关于血液恶性肿瘤免疫治疗的最新进展作...2016年是血液恶性肿瘤免疫治疗取得众多进展的一年,其中细胞免疫治疗和抗体免疫治疗尤为突出。本文将对近一年来已发表的以及第58届美国血液病学会(American Society of Hematology,ASH)会议中关于血液恶性肿瘤免疫治疗的最新进展作一综述。展开更多
1文献来源Prebet T,Sun Z,Ketterling RP,et al.Azacitidine with or without Entinostat for the treatmentof therapy-related myeloid neoplasm:Further resultsof the E1905 North American Leukemia IntergroupStudy[J].Br J Haem...1文献来源Prebet T,Sun Z,Ketterling RP,et al.Azacitidine with or without Entinostat for the treatmentof therapy-related myeloid neoplasm:Further resultsof the E1905 North American Leukemia IntergroupStudy[J].Br J Haematol,2016,172(3):384-391.2证据水平1b。3背景·治疗相关髓系肿瘤(therapy related myeloidneoplasm,t-MN),展开更多
1 文献来源
Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter...1 文献来源
Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial [ J]. Blood, 2007, 109(12) :5129-5135.展开更多
1文献来源
Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) [J]....1文献来源
Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) [J]. Cancer, 2007,109(10):2068-2076.展开更多
1 文献来源
M4 acute myeloid leukemia:The role of eosinophilia and cytogenetics in treatment response and survival The GIMEMA experience [J]. Haematologica, 2008, 93(7) : 1025 -1032.
1 文献来源
Btichner T, Berdel WE, Haferlach C, et al, Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leukemia Cooperative Group [J]. J Clin Onc...1 文献来源
Btichner T, Berdel WE, Haferlach C, et al, Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leukemia Cooperative Group [J]. J Clin Oncol, 2009,27(1):61-69.展开更多
1文献来源
Low-dose Interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. [J]. J Cl...1文献来源
Low-dose Interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. [J]. J Clin Oncol, 2008,12(26):4934-4939.展开更多
1文献来源
Pigneux A, Harousseau JL, Witz F, et al. Addition of Lomustine to Idarubicin and Cytarabine improves the outcome of elderly patients with De Novo acute myeloid leukemia: A report from the GOELAMS[J]. J Cl...1文献来源
Pigneux A, Harousseau JL, Witz F, et al. Addition of Lomustine to Idarubicin and Cytarabine improves the outcome of elderly patients with De Novo acute myeloid leukemia: A report from the GOELAMS[J]. J Clin Oncol, 2010,28(18):3028-3034.展开更多
1文献来源Rollig C,Serve H,Hüttmann A,et al.Addition of Sorafenib versus placebo to standard therapy in patients aged60 years or younger with newly diagnosed acute myeloidleukaemia(SORAML):A multicentre,phase 2...1文献来源Rollig C,Serve H,Hüttmann A,et al.Addition of Sorafenib versus placebo to standard therapy in patients aged60 years or younger with newly diagnosed acute myeloidleukaemia(SORAML):A multicentre,phase 2,randomised controlled tria[lJ].Lancet Oncol,2015,16(16):1691-1699.2证据水平1b。3背景·目前急性髓系白血病(acute myeloidleukemia,AML)的标准治疗方案是阿糖胞苷联合葸环类或者蒽醌类药物,展开更多
1文献来源
Faderl S, Ravandi F, Huang X, et al. A randomized study of Clofarabine versus Clofarabine plus low-dose Cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and...1文献来源
Faderl S, Ravandi F, Huang X, et al. A randomized study of Clofarabine versus Clofarabine plus low-dose Cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome [J]. Blood, 2008,112(5):1638-1645.展开更多
1 文献来源
Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2 169 unselected pediatric and ado...1 文献来源
Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2 169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 [J]. Blood,2008,111(9):4477-4489.展开更多
文摘2017年,在两款嵌合抗原受体T细胞免疫疗法(chimeric antigen receptor T-cell immumotherapy,CAR-T)细胞产品获批后,推进了全球细胞免疫治疗的研究。本文将对近一年来已发表的和第59届美国血液病学会(American Society of Hematology,ASH)会议中关于CAR-T细胞治疗血液恶性肿瘤的研究进展做一综述。
文摘1文献来源Prebet T,Sun Z,Ketterling RP,et al.Azacitidine with or without Entinostat for the treatmentof therapy-related myeloid neoplasm:Further resultsof the E1905 North American Leukemia IntergroupStudy[J].Br J Haematol,2016,172(3):384-391.2证据水平1b。3背景·治疗相关髓系肿瘤(therapy related myeloidneoplasm,t-MN),
文摘1 文献来源
Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial [ J]. Blood, 2007, 109(12) :5129-5135.
文摘1文献来源
Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) [J]. Cancer, 2007,109(10):2068-2076.
文摘1 文献来源
M4 acute myeloid leukemia:The role of eosinophilia and cytogenetics in treatment response and survival The GIMEMA experience [J]. Haematologica, 2008, 93(7) : 1025 -1032.
文摘1 文献来源
Btichner T, Berdel WE, Haferlach C, et al, Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leukemia Cooperative Group [J]. J Clin Oncol, 2009,27(1):61-69.
文摘1文献来源
Low-dose Interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. [J]. J Clin Oncol, 2008,12(26):4934-4939.
文摘1文献来源
Pigneux A, Harousseau JL, Witz F, et al. Addition of Lomustine to Idarubicin and Cytarabine improves the outcome of elderly patients with De Novo acute myeloid leukemia: A report from the GOELAMS[J]. J Clin Oncol, 2010,28(18):3028-3034.
文摘1文献来源Rollig C,Serve H,Hüttmann A,et al.Addition of Sorafenib versus placebo to standard therapy in patients aged60 years or younger with newly diagnosed acute myeloidleukaemia(SORAML):A multicentre,phase 2,randomised controlled tria[lJ].Lancet Oncol,2015,16(16):1691-1699.2证据水平1b。3背景·目前急性髓系白血病(acute myeloidleukemia,AML)的标准治疗方案是阿糖胞苷联合葸环类或者蒽醌类药物,
文摘1文献来源
Faderl S, Ravandi F, Huang X, et al. A randomized study of Clofarabine versus Clofarabine plus low-dose Cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome [J]. Blood, 2008,112(5):1638-1645.
文摘1 文献来源
Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2 169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 [J]. Blood,2008,111(9):4477-4489.